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Objective: Therapeutic angiogenesis is an alternative method of revascularization
for end-stage coronary artery disease. We determined the effects of intramyocardial
and intracoronary basic fibroblast growth factor 2 on myocardial blood flow and
function in a porcine model of hibernating myocardium.
Methods: Twenty-four mini-swine with 90% left circumflex artery stenosis and
documented hibernating myocardium by positron emission tomography and
dobutamine stress echocardiography were randomized to intramyocardial basic
fibroblast growth factor 2 at 0.6 g/kg (mid-dose, n  6, 30 injections/animal),
6 g/kg (high-dose, n  6, 30 injections/animal), or intramyocardial vehicle
control (n  6). The intracoronary group received 6 g/kg basic fibroblast
growth factor 2 (n  6) into the right and left circumflex artery coronary arteries.
Positron emission tomography and dobutamine stress echocardiography were
repeated at 1 and 3 months.
Results: In the vehicle group, normalized left circumflex artery myocardial blood
flow was 0.74  0.04 at 1 month and 0.75  0.07 at 3 months compared with 0.68
 0.03 at baseline. In the intracoronary group, myocardial blood flow was 0.71 
0.03 at 1 month and 0.72 0.04 at 3 months compared with 0.67 0.04 at baseline.
In the mid group, myocardial blood flow was 0.73  0.06 at 1 month and 0.85 
0.05 at 3 months (P  .001) compared with 0.67  0.04 at baseline. In the high
group, myocardial blood flow was 0.81  0.06 at 1 month and 0.83  .04 at 3
months (P  .03) compared with 0.71  0.02 at baseline. No significant improve-
ments in ischemia were demonstrated in any of the groups by dobutamine stress
echocardiography at 1 or 3 months.
Conclusions: In porcine hibernating myocardium, intramyocardial basic fibroblast
growth factor 2 significantly improved regional myocardial blood flow 3 months
after treatment. There was no significant change in function in any of the 4 groups.
These data suggest that intramyocardial dosing of basic fibroblast growth factor 2
(0.6 g/kg) may be an optimal dose for improving perfusion in the treatment of
end-stage coronary artery disease.
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Coronary artery disease continues to be themajor cause of mortality and morbidity inthe Western world despite continued ad-vances in the treatment of ischemic heartdisease. Nearly 13.5 million Americanssuffer from coronary artery disease; a
growing number of patients are unamenable to standard
therapy such as coronary artery bypass grafting or percuta-
neous coronary angioplasty because of diffuse disease and
poor runoff vessels on angiography, a lack of available
conduits, high operative risk, or various combinations of
these factors.1 An estimated 5% to 15% of patients under-
going coronary angiography may constitute this popula-
tion.2 Therapeutic angiogenesis may provide a novel ap-
proach to the treatment of myocardial ischemia for these
patients.
Therapeutic angiogenesis seeks to treat disorders of in-
adequate tissue perfusion through growth and proliferation
of new blood vessels.3 Angiogenesis is defined as the for-
mation of new blood vessels from preexisting vessels by the
process of cellular outgrowth. This process involves a com-
plex series of events including the following processes: the
breakdown of existing extracellular matrix; smooth muscle
and endothelial cell migration, adhesion, and proliferation;
the formation of new vascular structures; and the deposition
of new extracellular matrix.4 Basic fibroblast growth factor
(bFGF) has been studied both experimentally and clinically
utilizing various routes of delivery and doses for the treat-
ment of ischemic heart disease. bFGF is a single-chain,
heparin-binding, 16-kD 154 amino acid peptide with both
mitogenic and angiogenic properties. However, angiogenic
growth factors have been associated with pathologic angio-
genesis and tumorigenesis.5-10 The long-term efficacy of a
safe low dose of bFGF in hibernating myocardium remains
to be established.
A series of investigators have examined the effects of
recombinant bFGF in both swine and canine species using
an ameroid constrictor model.11-15 The longest period be-
tween treatment with bFGF and follow-up assessment of
perfusion and function was 8 weeks. Longer study periods
have been difficult to achieve as the ameroid model is
limited by the eventual development of a collateral circula-
tion to the ischemic areas of myocardium. Therefore, the
purpose of our study was to determine the longer-term
effects (3 months) of basic FGF-2 using either intramyocar-
dial and intracoronary (IC) delivery. To examine the long-
term effects of this exogenous protein on myocardial per-
fusion and function, we used a porcine model of hibernating
myocardium previously developed and validated in our
laboratory.
Methods
A total of 24 adult male mini-swine (25-35 kg) were used. Animals
were obtained from Harlan-Sinclair (Indianapolis, Ind) and housed
under standard conditions and fed a regular diet. The Animal Care
and Use Committee of Duke University approved all procedures
and protocols. Animals received humane care in compliance with
the Principles of Laboratory Animal Care formulated by the Na-
tional Society for Medical Research and the Guide for the Care and
Use of Laboratory Animals prepared by the Institute of Laboratory
Animal Resources and published by the National Institutes of
Health (NIH publication 85-23, revised 1996).
Partial Coronary Occlusion Model
All animals underwent induction of anesthesia with the combina-
tion tiletamine/zolazepam (5 mg/kg intramuscularly). Orotracheal
intubation was performed and anesthesia maintained with isoflu-
rane (2%) while the animals were mechanically ventilated. Con-
tinuous electrocardiographic and pulse-oximetric monitoring was
used throughout the procedure to ensure a stable cardiac rhythm
and adequate oxygenation. Ampicillin (1 g IV), gentamicin (80 mg
IV), and bretylium tosylate (5 mg/kg IV) were given preopera-
tively. Initial muscle relaxation was obtained with a single injec-
tion of pancuronium bromide (2 mg IV). Under sterile conditions,
a left anterolateral thoracotomy was performed through the third
intercostal space. The pericardium was incised longitudinally, and
the left atrial appendage was retracted to allow exposure of the left
circumflex coronary artery (LCX). The proximal LCX was dis-
sected free to allow placement of a hydraulic occluder and 2-mm
ultrasonic flow probe (Transonic Systems, Inc, Ithaca, NY) around
the vessel. The flow probe was placed distal to the occluder to
record downstream flow through the LCX. The pericardium was
closed. The occluder and flow probe were then exteriorized
through a separate stab incision. A 20-French chest tube was
placed and the wound closed in layers. The chest tube was re-
moved at the conclusion of the procedure. The animals were fitted
with specially designed jackets (Lomir Biomedical, Quebec, Can-
ada) to protect and allow easy access to their externalized hard-
ware.
Three days postoperatively the animals were lightly sedated
with the combination tiletamine/zolazepam (5 mg/kg intramuscu-
larly) and the occluder inflated to reduce resting blood flow in the
LCX downstream from the occluder to 10% of baseline as assessed
using the implanted flow probe. Once flow was stable for 5
minutes, the animals were returned to their cages. Flow was
rechecked the following day (postoperative day 4) and the oc-
cluder adjusted as needed to maintain a 90% flow reduction. This
generally required additional tightening due to capacitance of the
occluder. Flow was then rechecked again the following day (post-
operative day 5) to assure continued occlusion. No additional
occluder manipulation was performed after the second flow check.
Animals were then kept in this low-flow state for the duration of
the experiment. Animals were medicated with aspirin (650 mg po
every day) throughout the entire experiment.
Positron Emission Tomography and Dobutamine
Stress Echocardiography
Animals underwent baseline positron emission tomography (PET)
and dobutamine stress echocardiography (DSE) to characterize
myocardial blood flow, metabolism, and function as previously
described.16 This was performed 30 days postocclusion (postop-
erative day 34). PET scans were interpreted as showing hibernat-
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ing myocardium if a flow deficit was noted in the lateral and
posteroinferior walls of the left ventricle supplied by the LCX
accompanied by normal or increased glucose utilization in these
same regions (both as compared to the nonischemic septum).17
Using DSE, viability in the lateral and posteroinferior walls of the
left ventricle was defined as an improvement in systolic wall
thickening with low-dose dobutamine in myocardial regions with
severe hypocontractility at rest.18 Viable segments were consid-
ered ischemic if systolic wall motion deteriorated with stress
(biphasic response).19
After an overnight fast, dynamic PET emission imaging of the
heart was performed at rest for 20 minutes following a 30-second
IV infusion of 13N-ammonia (15-20 mCi). A 40-minute delay
followed for decay of 13N activity. Then dynamic imaging of the
heart for 60 minutes was performed following a 30-second infu-
sion of 18F-fluorodeoxyglucose (FDG; 10 mCi). All emission
images were corrected for photon attenuation using a transmission
scan. Time-activity curves of tracer concentration in the left ven-
tricular myocardium were obtained from short-axis views aver-
aged over 8 sectors in 3 short-axis slices (basal, mid, and apical,
Figure 1). Previously validated compartmental modeling tech-
niques were applied to the time-activity curves to obtain regional
estimates of myocardial blood flow (mL/g/min) and glucose utili-
zation (nmol/g/min).20,21 A “lumped constant” of 1.0 was assumed
for the calculation of glucose utilization from fractional FDG
uptake rate.22 During the PET scans, animals were maintained
under general anesthesia and mechanically ventilated as described
above. PET data was interpreted in a blinded manner both quali-
tatively by a physician experienced reading cardiac PET scans and
quantitatively using absolute values for blood flow (mL/g/min) and
glucose utilization (nmol/g/min). Absolute values of myocardial
blood flow and glucose utilization were compared within each
individual PET study to determine whether viability and ischemia
were present in the LCX distribution. For each study, sectors
representing the anterior septum (left anterior descending coronary
distribution) were used as the normal reference segments.
DSE
DSE was performed in 3-minute stages with incremental doses of
dobutamine beginning with 5 g/kg/min and increasing to 40
g/kg/min. Based on a standard 16-segment model, wall motion
was graded as 1  normal, 2  hypokinetic (reduced systolic
wall thickening), 3  akinetic (absent systolic wall thickening),
or 4  dyskinetic (outward systolic wall motion). Regional wall
motion score index (WMSI) was calculated at rest, low dose,
and peak stress. Animals were sedated with the combination
tiletamine/zolazepam (5 mg/kg intramuscularly) prior to DSE.
A single cardiologist blinded to the clinical status of the mini-
swine and with expertise in stress echocardiography interpreted
the echoes.16
Growth Factor Delivery
After partial left circumflex arterial occlusion and subsequent
documentation of myocardial hibernation by PET and DSE, each
animal was randomized to receive recombinant human bFGF or
vehicle via 1 of 4 groups: high-dose intramyocardial (IM) bFGF (6
g/kg), mid-dose IM bFGF (0.6 g/kg), IC bFGF (6 g/kg), or IM
vehicle injection. The second operation was performed within 3
days of completion of baseline studies. Anesthesia, preoperative
medications, and intraoperative monitoring were as described as
above. Baseline systolic blood pressure, heart rate, serum chem-
istries, and bFGF-2 serum levels were measured immediately after
the induction of general anesthesia. Intramyocardial bFGF or ve-
hicle was administered at the above doses to treat the entire LCX
region via 30 0.1-mL intramyocardial injections at 1-cm intervals.
Care was taken to avoid all epicardial and intramyocardial vessels.
Hemostasis was obtained by manual compression. The occluder
and flow probe were left intact. The pericardium was left widely
open. Repeat systolic blood pressure and heart rate were measured
immediately after bFGF or vehicle injection. The wound was
closed as described previously. The animals were kept under
general anesthesia for 2 hours after intramyocardial injection and
Figure 1. Diagram of the 8 sectors used for comparing quantitative measurements of myocardial blood flow and
glucose utilization in the 3 short-axis slices (basal, mid, and apical). Sectors 2 through 4 (lateral and posteroinferior
walls of the left ventricle) were considered as representing myocardium within the left circumflex distribution.
Sectors 7 and 8 served as the nonischemic control regions.
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repeat measurements of serum chemistry, heart rate, and systolic
blood pressure were repeated. Continuous LCX occlusion was
confirmed postoperatively by weekly flow monitoring with the
flow probe.
IC bFGF was delivered to 6 animals with hibernating circum-
flex myocardium using a sterile femoral artery cut-down and the
Judkins technique. The animals were under general anesthesia
during this procedure. Heparin 70 U/kg was given intravenously
immediately prior to the femoral artery cut-down. Systolic blood
pressure, heart rate, serum chemistries, and bFGF serum levels
were collected immediately after the femoral arterial sheath was
placed. The coronary artery anatomy was reassessed prior to bFGF
delivery. Near total occlusion of the LCX with minimal collater-
alization was demonstrated with antegrade flow down the LCX
artery. Six g/kg bFGF was divided into 2 injections and delivered
into the left circumflex artery over a 10-minute period, followed by
the right coronary injection over a 10-minute period. Systolic
blood pressure and heart rate were measured in between the LCX
and right coronary artery injections. Next, the groins were closed
and the animals kept under general anesthesia for 2 hours, after
which measurements of serum chemistry, systolic blood pressure,
and heart rate were repeated.
Follow-up PET and DSE
One and 3 months after the second procedure, the bFGF- and
vehicle-treated animals had repeat PET and DSE as described
previously. To allow comparisons between studies performed at
baseline and 1 and 3 months postoperatively and to correct for
known interstudy variability of absolute values of myocardial
blood flow obtained by PET,17,23 the data were normalized using
previously described techniques.17 For each study, sectors repre-
senting the anterior septum (sectors 7 and 8 in Figure 1) were used
as the normal reference segments. 13N-ammonia activity in the
sectors representing the LCX distribution (sectors 2 to 4 in Figure
1) was then expressed as a percentage of the activity measured in
the reference segments.
Animal Death
Three months after the second procedure, the animals were killed
under general anesthesia. Cardiac catheterization was performed
via the Judkins technique and the hearts were explanted through a
median sternotomy. Sections of the left ventricle were frozen in
liquid nitrogen, as well as placed in sucrose solution for alkaline
phosphatase staining for vascular density analysis.
Vascular Density Analysis
To further describe differences in neovascularization in treated
ischemic myocardium, we made a comprehensive comparison of
neovessel density in these regions. Using previously described
techniques,24 vascular density was measured by endogenous en-
dothelial alkaline phosphatase staining on unfixed frozen sections
of the left ventricles in the bFGF and IM vehicle groups. Vascular
density was measured by counting. From each animal, samples
were examined from the LCX ischemic distribution. Six random
high-power (200) fields were examined per sample and quanti-
tated using an NIH imaging program (version 1.62).
Statistical Analysis
Data were analyzed using Sigmastat for Windows version 2.0
(SPSS Inc, Chicago, Ill). All data are presented as the mean 
standard error of the mean. Baseline and 1- and 3-month PET data
was compared within groups using 1-way repeated measures anal-
ysis of variance (RM ANOVA) followed by the Tukey method for
multiple comparison procedure. DSE regional WMSI in the base
and mid portions of the lateral, posterior, and inferior segments of
the left ventricle were compared at baseline and 1 and 3 months
using 1-way RM ANOVA followed by the Tukey tests for multiple
comparison procedure. Vascular density was compared by
Kruskal-Wallis 1-way ANOVA on ranks with post hoc Tukey
tests. Statistical significance was considered a P value less than
.05.
Results
All but 2 of the animals enrolled in this study survived to the
3-month end point. Two animals died 1 month after IC
bFGF delivery secondary to sepsis from infected groin
wounds. No abnormal adverse events were noted during the
entire course of these experiments in those animals that
survived the study.
PET
Analysis of quantitated normalized LCX myocardial blood
flow 1 and 3 months following IM vehicle revealed a slight
increase in normalized 13N-ammonia accumulation similar
to that seen at baseline (Table 1). Resting myocardial blood
flow was not significantly improved in the IC and vehicle
groups at both 1 and 3 months after treatment (P  .38 and
.41, respectively, by 1-way RM ANOVA; Figure 2). How-
ever, at 3 months following both high- and mid-dose IM
bFGF, there was a significant improvement (27.8%  5.2%
and 16.6%  5.0%, respectively) in LCX resting myocar-
dial blood flow (MBF) (P .001 and P .033, respectively
by 1-way RM ANOVA), which was not demonstrated at the
1-month time point.
TABLE 1. Normalized myocardial perfusion by positron
emission tomography for left circumflex artery distribution
preoperatively and 1 and 3 months postoperatively follow-
ing treatment
Treatment group
Perfusion ratio
Baseline
1 month
posttreatment
3 months
posttreatment
High (n  6) 0.71 0.02 0.81 0.06 0.83 0.04*
Mid (n  6) 0.67 0.04 0.73 0.06 0.85 0.05*
IC (n  6) 0.67 0.04 0.71 0.03 0.72 0.04
Vehicle (n  6) 0.68 0.03 0.74 0.04 0.75 0.07
IC, Intracoronary. Normalized myocardial perfusion mean blood flow left
circumflex distribution  mean blood flow nonischemic septum, in mL/g/
min. Values reported as the mean  standard error of the mean.
*P .033 and P .001 for the high and mid groups, respectively, by 1-way
repeated measures ANOVA.
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Table 2 summarizes the FDG accumulations in the 24
animals. There was normal to increased FDG uptake in the
area of LCX perfusion abnormality (mid-base regions)
when compared with the apical regions, which was consis-
tent with hibernating myocardium in the LCX distribution.
DSE
Baseline DSE demonstrated severe hypocontractility at rest
in the lateral and posteroinferior walls of the left ventricle
supplied by the partially occluded LCX coronary artery in
all 4 groups (Figure 3). Wall motion in these regions dem-
onstrated a biphasic response of initial improvement fol-
lowed by deterioration with dobutamine stimulation (Table
3), which is consistent with ischemic, viable myocardium in
the LCX distribution.
For the IM vehicle control, mid-dose IM bFGF, high-
dose IM bFGF, and IC bFGF groups at 1 and 3 months
following injection, there was no significant reduction in
ischemia in either resting or peak stress regional WMSI
(Table 3).
Vascular Density
Quantitative vascular density (arbitrary units) by 1-way
ANOVA on ranks demonstrated significantly higher left
ventricular neovascularization in the mid group when com-
pared to the high, IC, and vehicle groups (P  .001, Table
4) by Kruskal-Wallis 1-way ANOVA on ranks with Tukey
tests for multiple comparison procedures (Figure 4). These
findings are consistent with the observed qualitative differ-
ences and provide further evidence for neovascularization
within areas of ischemic, viable myocardium treated with
mid-dose IM bFGF.
Chemistry and Hemodynamic Data
Tables 5, 6, 7 , and 8 summarize the serum chemistry and
hemodynamic data, respectively, obtained during the course
of the study.
In terms of serum chemistry changes in the high group,
only serum glucose levels were significantly different at the
2-hour time point versus baseline (P  .04 by 1-way RM
ANOVA). For the mid group and the IM vehicle group,
there were no significant changes noted. With respect to
hemoglobin, platelets, sodium, CO2, and creatinine at base-
line, 2 hours, and 3 months, no significant changes were
noted. No significant heart rate changes were observed in
either the high, mid, or IC group with respect to control
animals. Similarly, systolic blood pressure (SBP) was not
significantly altered in any of the treatment arms in any of
the measured time points.
Serum bFGF-2 Levels
Table 9 summarizes serum bFGF-2 levels at baseline and
at 3 months after treatment. Only the IC bFGF group had
a significantly higher bFGF-2 level at 3 months when
compared with baseline (P  .038 by 1-way RM
ANOVA). The high, mid, and vehicle groups had serum
bFGF-2 levels that were unchanged from baseline when
compared at 3 months.
TABLE 2. 18F-fluorodeoxyglucose measurements
Treatment group Apex Mid-base
High (n  6) 1.72 0.25 1.50 0.33
Mid (n  6) 1.84 0.57 1.48 0.35
IC (n  6) 1.08 0.12 3.11 0.90
Vehicle (n  6) 1.83 0.28 2.11 0.71
IC, Intracoronary. Values reported as the mean  standard error of the
mean.
Figure 2. PET perfusion at baseline and 3 months after treatment. The high and mid groups had significantly
improved perfusion 3 months after treatment.
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Discussion
In this study, mid-dose bFGF (0.6 g/kg) improved resting
myocardial blood flow by PET 3 months after direct in-
tramyocardial injection. However, no significant improve-
ments were seen in the resting wall motion abnormalities at
either mid- or high-dose bFGF as evaluated by DSE. Vas-
cular density analysis revealed significantly higher left ven-
tricular neovascularization following IM mid-dose bFGF
when compared with IM high dose (6 g/kg), intracoronary
(6 g/kg) bFGF, and IM vehicle control. Lastly, the serum
chemistry and hemodynamic data revealed no adverse ef-
fects of mid-dose, high-dose, and IC bFGF-2 over the 3
month time course.
Previous investigators have utilized the ameroid con-
strictor model for evaluation of angiogenic growth factors.
Harada and colleagues11 demonstrated in swine that 4 to 5
g bFGF delivered periadventitially via heparin-alginate
beads improved coronary flow and reduced infarct size with
prevention of pacing-induced hemodynamic deterioration
up to 8 weeks after surgery. Unger and associates13 in 1994
utilized a similar ameroid constrictor model in dogs and
demonstrated using 110 g bFGF via intracoronary delivery
distal to the occluded left circumflex artery enhanced max-
imal collateral blood flow 4 weeks after treatment. In 1997,
Lopez and colleagues12 studied swine using 10 or 100 g
bFGF; at 8 weeks follow-up they demonstrated higher an-
giographic collateral index, improved thrombosis in myo-
cardial infarction (TIMI) flow scores and coronary flow
compared with controls, and improved regional and global
left ventricular function with significantly better preserva-
tion of regional wall motion in the 100-g group. Using a
swine ameroid model, Laham and colleagues demonstrated
significant increases in left-to-right angiographic collaterals
and left circumflex artery blood flow with intrapericardial
bFGF at 30 g, 200 g, and 2 mg. These improvements
translated into improved myocardial perfusion and function
with histological evidence of increased myocardial vascu-
Figure 3. Peak stress function as measured by dobutamine stress echocardiography. No improvement was seen
in peak stress function in any of the 4 groups as measured by dobutamine stress echocardiography.
TABLE 3. Mean regional wall motion score index preop-
eratively and 1 and 3 months postoperatively following
treatment
Treatment Rest Peak stress
High
LCX baseline 2.2 0.1 2.0 0.1
LCX 1 month 2.1 0.1 1.8 0.2
LCX 3 months 2.0 0.1 1.9 0.2
Mid
LCX baseline 2.1 0.1 1.8 0.1
LCX 1 month 2.1 0.1 1.7 0.2
LCX 3 months 2.1 0.1 1.8 0.2
IC
LCX baseline 2.2 0.1 2.0 0.2
LCX 1 month 2.2 0.1 2.0 0.2
LCX 3 months 2.3 0.1 2.2 0.2
Vehicle
LCX baseline 2.3 0.1 2.0 0.1
LCX 1 month 2.2 0.1 1.9 0.2
LCX 3 months 2.0 0.1 2.1 0.1
LCX, Left circumflex coronary artery. Wall motion scores: 1  normal; 2 
hypokinetic; 3  akinetic; 4  dyskinetic. Values reported as the mean 
standard error of the mean.
TABLE 4. Vascular density analysis for evidence of neo-
vascularization
Treatment group Quantitative vascular density
High (n  6) 1561.8 76.1
Mid (n  6) 2286.0 100.5*
IC (n  6) 1821.4 133.7
Vehicle (n  6) 1789.3 103.7
IC, Intracoronary. Quantitative vascular density analysis reported as the
mean  standard error of the mean, in arbitrary units.
*P  .04 by 1-way ANOVA on ranks versus all other groups.
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larity without any adverse effects 4 weeks after treatment.25
Left atrial delivery of 1.74 mg bFGF in canines resulted in
a faster improvement in collateral circulation flow that was
accompanied by an increase in neovascularization up to 4
weeks after treatment. However, no functional benefits were
demonstrated.15 Lastly, Rajanayagam and colleagues26 uti-
lized in canines 4 routes of delivery of bFGF (central
venous injection 1740 g/d for 1, 2, or 7 days; intravenous
infusion 100 g/kg/d for 7 days; pericardial instillation
2000 g/d for 7 days; and intracoronary injection 100
g/kg/d for 1 or 2 days). Using microspheres, maximal
collateral perfusion with intracoronary infusion for 2 days
exceeded that of control dogs by 31%. Perfusion was not
increased following single-dose intracoronary bFGF, and
central venous, intravenous, and pericardial injections failed
to enhance collateral perfusion.26
The ameroid constrictor model remains the most widely
used animal model of chronic myocardial ischemia in ex-
amining changes in perfusion and function following the
administration of angiogenic growth factors, as discussed
above. These constrictors are commonly used in swine
because of their coronary anatomy, which has minimal
preexisting coronary collateral vessels and is similar to
human coronary anatomy. Inherent limitations to the use of
these occluders include an inability to control the rate or
degree of coronary occlusion, which sometimes results in
complete vascular occlusion.27-29 Also, there is a large
variation in the reported percent infarction of the area at risk
(5% to 100%).30 Myocardial blood flow and function at rest
after ameroid-induced coronary occlusion have been dem-
onstrated to be normal by some investigators due to exten-
sive coronary collateral development.30,31 Although the
Figure 4. Vascular density analysis. Vascular density counts in each of the 4 groups demonstrated a significant
increased neovessel count in the mid group when compared to the high, IC, and vehicle controls.
TABLE 5. Serum chemistry data: Hgb, Hct, Plt, and WBC measured at baseline and 2 hours and 3 months following
treatment
Treatment group Hgb Hct Plt WBC
High (n  6)
Baseline 10.9 0.8 36.0 2 472.2 64.4 11.3 0.8
2 hours 9.8 1.3 32.2 4.0 354.7 52.5 13.0 2.4
3 months 12.1 1.4 39.0 4.4 437.3 45.4 12.6 1.0
Mid (n  6)
Baseline 11.7 0.5 37.8 1.7 489.2 73.8 13.2 1.0
2 hours 10.4 0.2 34.0 0.6 479.7 56.9 13.2 1.3
3 months 11.4 0.6 37.3 1.5 524.5 31.1 20.2 6.5
IC (n  6)
Baseline 10.7 0.1 34.5 0.3 427.8 40.1 15.4 4.8
2 hours 10.7 0.4 34.3 0.6 432.3 37.1 15.7 4.1
3 months 9.9 0.9 32.7 3 411.7 99.8 12.3 3.4
Vehicle (n  6)
Baseline 10.3 0.4 33.0 1.3 442.5 7.8 14.3 1.4
2 hours 10.4 0.4 33.5 1.3 408.8 13.7 14.9 1.7
3 months 11.6 0.2 36.7 0.6 337.0 17.2 10.8 1.8
IC, Intracoronary. Values reported as the mean  standard error of the mean.
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ameroid model is generally accepted as appropriate for
short-term investigations of ischemic myocardium, our par-
tial occlusion model of hibernating myocardium overcomes
many of the limitations of the ameroid model. For instance,
with our model we are able to control both the rate and
degree of coronary occlusion. Furthermore, we have been
able to validate the presence of resting myocardial ischemia
with viability in the left circumflex artery distribution, with
only a small 8% degree of subendocardial infarction.16
Thus, our model is well-suited for studies that involve a
longer time period between treatment of ischemic myocar-
dium by angiogenic mechanisms and follow-up functional
assessment. For example, our model has been able to dem-
onstrate improved myocardial blood flow and improved
wall motion 6 months following transmyocardial laser re-
vascularization (TMR).32 Our current study was able to
demonstrate a similar reversibility of stress-induced isch-
emia at 3 months.
Intramyocardial mid-dose bFGF may be a novel thera-
peutic option for end-stage coronary artery disease. Both
experimentally and clinically, bFGF doses have ranged
from 4 g to upward of 14-mg total dose for ischemic heart
disease. Systemic administration of bFGF in amounts nec-
essary to achieve therapeutic myocardial angiogenesis re-
quires large, often daily injections with the potential for
systemic toxicity including profound hypotension, hemato-
TABLE 6. Na, K, Cl, CO2, BUN, Cr, and glucose measured at baseline and 2 hours and 3 months following treatment
Group Na K Cl CO2 BUN Cr Glucose
High
Baseline 137.5 1.3 4.3 0.3 98.3 0.6 32.3 0.8 10.5 1.3 1.3 0.1 68.5 8.2
2 hours 139.2 1.8 3.9 0.3 98.6 1.8 32.8 1.3 10.2 1.0 1.2 0.1 93.2 6.1*
3 months 142.5 1.6 3.9 0.2 104.2 1.4 26.8 2.5 11.6 3.6 1.5 0.1 67.0 9.5
Mid
Baseline 138.5 1.3 4.9 0.2 98.7 1 31.5 0.7 11.3 2.0 1.5 0.1 71.8 3.9
2 hours 138.2 0.9 4.8 0.3 98.8 1.8 31.2 1.5 10.0 1.7 1.3 0.1 73.8 6.2
3 months 140 1.9 4.5 0.2 98.2 1.6 26.8 0.6 9.0 0.9 1.5 0.3 79.0 7.4
IC
Baseline 140.0 1.5 4.5 0.5 99.5 0.9 32.3 1.9 11.5 0.3 1.5 0.2 78.0 4.4
2 hours 139.0 2.1 3.6 0.3 98.5 0.7 33.0 1.9 11.5 0.3 1.5 0.1 75.8 4.6
3 months 139.3 0.7 4.7 0.6 98.6 0.9 30.6 1.0 10.6 1.7 1.6 0.1 74.0 7
Vehicle
Baseline 137.7 1.1 4.2 0.2 96.5 0.6 35.2 1.3 8.7 1.8 1.2 0.1 69.2 6.1
2 hours 137.0 1.4 4.7 0.4 96.0 1.0 34.5 1.5 8.2 1.3 1.1 0.1 76.5 6.9
3 months 140.5 0.7 4.4 0.2 100.8 1.1 30.3 0.7 9.0 1.2 1.6 0.1 83.3 8.1
IC, Intracoronary. Values reported as the mean  standard error of the mean.
*P  .04 by 1-way repeated measures ANOVA.
TABLE 7. CK, CK/MB, and troponin T measured at baseline and 2 hours and 3 months following treatment
Treatment group CK CK-MB Troponin T
High (n  6)
Baseline 621.3 281.2 4.0 0 0.01 0.1
2 hours 2532.6 1263.7 4.7 0.2 0.02 0.1
3 months 857.0 36.8 5.6 1.3 0.02 0.1
Mid (n  6)
Baseline 2663.5 872.0 3.8 0.6 0.01 0.1
2 hours 1710.5 422.1 3.7 0.8 0.02 0.1
3 months 756.5 458.7 3.5 0.6 0.01 0.1
IC (n  6)
Baseline 677.0 238.4 6.3 3.9 0.01 0.1
2 hours 888.0 441.5 6.0 3.0 0.01 0.1
3 months 1553.8 918.5 12.7 9.1 2.6 2.6
Vehicle (n  6)
Baseline 3744.5 1360.5 2.8 0.3 0.01 0.1
2 hours 4021.0 1327.1 2.5 0.5 0.01 0.1
3 months 602.2 151.2 2.7 0.3 0.01 0.1
CK, Creatine kinase; CK-MB, creatine kinase MB isoenzyme; IC, intracoronary. Values reported as the mean  standard error of the mean.
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logical, and renal end-organ toxicity. There has been con-
cern about potential acceleration of occult neoplastic dis-
ease or diabetic retinopathy with the use of angiogenic
growth factors. In addition, the mitogenic effects of angio-
genic growth factors (mostly vascular endothelial growth
factor) may accelerate atherosclerotic lesion expansion
and/or may lead to plaque destabilization, as demonstrated
by a series of investigators.33,34Lastly, administration of
bFGF in high dosages is also associated with numerous side
effects including anemia, thrombocytopenia, membranous
nephropathy, and hyperostosis.35
Though we did not examine specific end-organ toxicity,
local administration of very low doses of bFGF into the
myocardium may provide the safest means of delivery of a
potentially toxic medication. The main strength of the cur-
rent study is the long time period between treatment with
bFGF and follow-up measurement of PET and DSE. To our
knowledge, no other investigator has demonstrated the ef-
fects of exogenous growth factor administration as long as
3 months after treatment. Despite this strength, we were not
able to show that the increased myocardial perfusion found
after mid- or high-dose intramyocardial bFGF therapy trans-
lates into improved systolic function. Perhaps an even
longer follow-up period may be required to show such
benefit. We have also demonstrated a potential link between
capillary density and increased regional perfusion, as was
demonstrated in the mid-dose IM bFGF group. Thus, the
neovascularization that results from exogenous angiogenin
administration may be directly responsible for the improve-
ment in regional perfusion found after such intervention.
The main limitation of our study, however, was our
inability to show this link between improved capillary den-
sity and increased myocardial perfusion in the high-dose IM
bFGF group. One potential reason for this inconsistency
may have been the random tissue sampling technique used
in our vascular density analysis.
In summary, we have shown that high- and mid-dose
bFGF-2 delivered by direct intramyocardial injection results
in significant improvement in perfusion of chronically isch-
emic porcine myocardium 3 months later. Meanwhile, in-
tracoronary infusion of this growth factor does not appear to
significantly augment such perfusion. The increase in myo-
cardial blood flow achieved by IM bFGF did not result in
improved contractile function of that myocardium, indicat-
ing that the functional benefits of bFGF therapy may require
longer time periods to develop.
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